The efficiency targeting IL-33 (itepekimab) and its receptor (astegolimab) for asthma have been confirmed in clinical trials (138), while they are failed to reach statistical significance in AD except etokimab (a humanized anti-IL-33 monoclonal antibody). This evidence concerns the gene IL33 and Alzheimer disease.